January 10, 2017

FierceBiotech Executive Breakfast
DECIPHERING IMMUNO-ONCOLOGY:
TRENDS IN DEAL-MAKING AND R&D

The Fairmont | Grand Ballroom | San Francisco

 REGISTRATION FULL 

About

FIERCEBIOTECH RETURNS TO SAN FRANCISCO DURING JP MORGAN 2017

Checkpoint inhibitors were a start for immunotherapies in cancer—but it's clear that the best way to manipulate the immune system to better defend against cancer is to intervene in multiple ways in the immune response pathway. A number of approaches are in the works including a variety of cell-based therapies, antibodies, small molecules and vaccines. Major cancer players Bristol-Myers Squibb, Merck, Genentech and Celgene have been making their bets, as have Wall Street and VCs. We’ll examine the relative strengths and weaknesses of various strategies in development—and how they’re likely to fit together, as well as the wheeling-and-dealing that’s aiming to get us there.

Speakers

OPENING REMARKS:
Michael Mentesana

Principal, Pharmaceutical & Life Sciences R&D Advisory Services
PwC
Michael is a dynamic consulting executive with more than eighteen years of experience assisting organizations improve business performance by leading the development and deployment of new strategies, processes, and enabling technology. He has global experience in the financial services, consulting, biopharmaceuticals and medical device industries. Currently, Michael is the Pharmaceutical and Life Sciences R&D Advisory Services Leader for PricewaterhouseCoopers’ and is based in New York City. Michael is primarily focused on pharmaceutical research and development and his expertise ranges from strategic business planning, to predictive analytics, to outsourcing strategy and specific R&D compliance challenges.

His areas of R&D specialization include: TA strategy, restructuring and diligence, operations planning, data analytics protocol design, trial recruitment, senior-management decision support, demand management, portfolio strategy & visualization, organization design, capacity planning, and process engineering. Prior to joining PwC, he was the founder and president of Intendere Consulting, a specialized consultancy established to develop and execute practical R&D services and strategies for pharmaceutical and biotechnology companies. Earlier in his career he was a management consultant in the Life Science Strategy practice at Deloitte Consulting based in New York City. Currently, Michael is leading several projects dealing with R&D operations transformation, predictive R&D analytics, CRO outsourcing strategies and R&D compliance initiatives. Throughout the past few years Michael has been the chief architect for some of the largest R&D operations transformations done in the industry.

Michael holds a B.S. in Industrial / Organizational Psychology and a B.S. in Biology from Brooklyn College and a M.A. in Organization Psychology from Columbia University. He is a visiting professor for several universities and teaches Operations, Organization Behavior and Leadership. Michael also serves on the board of the American Humane Association.

Rich Murray

CEO
Jounce Therapeutics
Richard Murray brings to Jounce more than two decades of experience building biologics, R&D capabilities, and moving exciting science through development for both startup biotechnology and large pharmaceutical companies. Dr. Murray joined Jounce from Merck, where he most recently served as senior vice president, biologics & vaccines research, and was a member of the Merck Research Laboratories (MRL) leadership team. There, he was responsible for the advancement of protein therapeutics and vaccines across a breadth of therapeutic areas, from discovery through development and manufacturing, including Merck’s immunotherapy programs. Prior to joining Merck, Dr. Murray provided strategic and operational guidance to protein therapeutic biotech companies and served as an advisor to venture capital and life science investors. He was the executive vice president and chief scientific officer at PDL BioPharma, and previously, he was co-founder and vice president of research at EOS Biotechnology, which was acquired in 2003 by Protein Design Labs. Prior to these executive level roles, he spent more than 10 years on the staff at DNAX Research Institute, which later became Schering Plough Biopharma, and now represents the main site for Merck’s Biologics discovery efforts.

Dr. Murray holds a Ph.D. in microbiology and immunology from the University of North Carolina at Chapel Hill and a B.S. in microbiology from the University of Massachusetts, Amherst.

Terry Rosen

CEO
Arcus Biosciences
Terry has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for over 30 years. In 2015, he co-founded Arcus Biosciences, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. Previously, he was co-founder and CEO of Flexus Biosciences, a company created to develop small-molecule drugs to reverse tumor immunosuppression, which was acquired by Bristol-Myers Squibb early in 2015 for $1.25 billion.

Prior to Flexus, Terry served as Vice President, Therapeutic Discovery (TD) at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004. He was named Amgen Washington site head in 2006, transitioned to a leadership role heading Chemistry Research and Discovery in 2007 and became the head of Protein Sciences in 2011. He and his leadership team were responsible for the creation of the TD organization, a group of 550+ staff responsible for all of Amgen's large and small molecule drug discovery efforts.

Prior to joining Amgen, Terry held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry. He has also held scientific and management positions at Pfizer and Abbott Laboratories. Terry serves on the Salk Institute Board of Trustees, the leadership committees of the University of Michigan Undergraduate Research Opportunity Program and Life Sciences Institute, the Berkeley Chemistry Advisory Board, the Caltech Biology & Bioengineering Chair’s Council and the Board of the California Life Sciences Association.

Paul Biondi

Head of Business Development
Bristol Myers-Squibb
Paul Biondi is currently senior vice president, Head of Business Development for Bristol-Myers Squibb and is responsible for leading the development of strategic partnerships and pursuing external scientific innovations across commercial, development, discovery and technology platforms to complement the company’s internal R&D pipeline. With deep knowledge of the company’s R&D strategy and portfolio, strong business expertise and understanding of the healthcare landscape, Paul is focused on external innovation that helps Bristol-Myers Squibb develop and deliver transformational medicines for patients with serious diseases.

Prior to this recent appointment, Paul led the R&D Operations organization at Bristol-Myers Squibb for 10 years working for the Head of R&D at BMS and providing strategic insights and operational excellence to enhance the performance of the R&D organization. As head of R&D Operations he was responsible for optimizing the delivery of the company’s pipeline, managing the company’s R&D portfolio and delivering early- and late-stage clinical operations. He also had responsibility for cross R&D efforts around strategy, analytics, continuous improvement, learning and collaboration. In this role, Paul worked closely with the Business Development leaders in formulating portfolio and disease specific strategies as well as overseeing all integrations of any scientific assets or R&D companies.

Biondi joined Bristol-Myers Squibb in 2002 and was appointed vice president of R&D Operations when it was formed in May 2005. He was promoted to senior vice president of R&D Operations in 2010. Paul was appointed senior vice president, Head of Business Development in October2015.

Biondi holds a bachelor’s degree in government and economics from Dartmouth College and an M.B.A. from J.L. Kellogg School of Management at Northwestern University..

Cary Pfeffer

Partner
Third Rock Ventures
Cary Pfeffer joined Third Rock Ventures at its inception in 2007 and has more than 20 years of business development and transaction experience, along with a broad array of biotech product development experience. Cary leads the partner development efforts, including building and maintaining strong relationships with large biotech and pharmaceutical companies. He has played an instrumental role in a number of innovative alliances and collaborative company building efforts across a portfolio of products and services, including an industry-leading global strategic collaboration between Agios and Celgene in the field of cancer metabolism. Cary supports and advises on business development efforts and has also assumed active leadership roles in other portfolio companies, functioning as chief executive officer and chief business officer through the first 12-18 months after launch.

Before joining Third Rock, Cary founded The Pfeffer Group, a boutique consulting firm that provided business development and strategy advisory services, completing multiple transactions for leading biotechnology and life sciences companies. Prior to that, Cary spent more than a decade at Biogen where he held a variety of senior and executive level U.S. and global management roles focused on business and market development, product development and commercial operations. Earlier in his career, Cary spent several years in corporate finance in the Health Care Investment Banking Group of Lehman Brothers. He earned his M.D. from the University of Pennsylvania, his MBA from the Wharton School of the University of Pennsylvania and holds a B.A. in biochemistry from Columbia University.

CLOSING REMARKS: 
Mark Reisenauer

Senior Vice President, Oncology Business Unit
Astellas
Mark Reisenauer is senior vice president, oncology business unit. In this role, he is responsible for commercial activities supporting marketed products, Astellas' co-promotion partners and commercial planning for early stage oncology development compounds. Reisenauer is a member of the Astellas US Management Committee.

Reisenauer joined Astellas in 2011 as vice president, sales and marketing, oncology, where he led commercial activities supporting oncology products, Tarceva and the launch of Xtandi.

Prior to joining Astellas, Reisenauer served as senior vice president and chief commercial officer of Micromet Inc. (now part of Amgen), where he led investor and public relations, new product planning, and commercial launch planning. Previously, Reisenauer held various sales and marketing leadership roles at Abbott, Pharmacia, Bristol-Myers Squibb and AstraZeneca.

Reisenauer earned a bachelor’s degree in political science from the University of Wisconsin.

Carly Helfand
(Moderator)

Senior Editor
FiercePharma
Carly Helfand is a news editor with FierceMarkets' Life Sciences group, writing for FiercePharma and FiercePharma Marketing. Carly got her start covering pharma while earning her master's at Northwestern University's Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post's Wonkblog and Cape Town's Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle.

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

schedule

  • 7:00 AM - 7:30 AM: Registration, Networking & Full Breakfast Buffet
  • 7:30 AM - 8:30 AM: Panel Discussion

sponsors

Pricing

Insider Rate

$119 per person

Or

Early Bird Rate

$139 per person

Or

Regular Rate

$149 per person

Insider Rate Ends November 18, 2016
Early Bird Rate Ends December 2, 2016

location

FAQ

Yes, valet parking is available for an additional fee.

Yes, a full breakfast will be served from 7:00 a.m. - 7:30 a.m.

Attendee substitutions may be made on or before January 6, 2017. Please submit a written request by email to events@fiercemarkets.com.

Due to the nature of this event, we are unable to provide refunds. Attendee substitutions may be made on or before January 6, 2016. Please submit a written request by email to events@fiercemarkets.com.